Fulcrum Therapeutics (FULC) Equity Average (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Equity Average data on file, last reported at $341.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $341.2 million, up 44.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $341.2 million (up 44.7% YoY), and the FY2025 annual result was $296.0 million, up 23.8% from the prior year.
• Equity Average improved to $341.2 million in Q1 2026 per FULC's latest filing, from $273.7 million in the prior quarter.
• Over five years, Equity Average peaked at $341.2 million in Q1 2026 and troughed at $175.0 million in Q2 2022.
• A 5-year average of $240.2 million and a median of $243.7 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 79.74% in 2022, then slipped 22.28% in 2025.
• A 5-year view of Equity Average shows it stood at $210.2 million in 2022, then advanced by 16.72% to $245.3 million in 2023, then grew by 1.97% to $250.2 million in 2024, then climbed by 9.4% to $273.7 million in 2025, then advanced by 24.65% to $341.2 million in 2026.
• Business Quant data shows FULC's Equity Average at $341.2 million in Q1 2026, $273.7 million in Q4 2025, and $206.4 million in Q3 2025.